Biora Therapeutics Inc (BIOR) - News Archive

Biora Therapeutics Secures Funding Agreement to Continue its Path to Pharma PartnershipIn a significant milestone for Biora Therapeutics, the biotechnology company announced a new funding agreement with its existing inv...

: In recent developments, Biora Therapeutics has unveiled supplemental data from its Phase 1 clinical trial of BT-600, presented at a Key Opinion Leader (KOL) event. BT-600, utilizing the innovative NaviCap platform, sh...

Biora Therapeutics Revolutionizes Colon Delivery of Therapeutics with Positive Clinical Trial Results for BT-600 and the NaviCap PlatformBiora Therapeutics, a leading biotechnology company, recently announced positive c...

Biora Therapeutics, a leader in innovative drug delivery solutions, has announced a significant milestone in its mission to revolutionize oral drug delivery systems. The company is set to present preclinical data on the...

Revolutionizing Colon Therapeutics: Biora Therapeutics NaviCap Platform Shows Promising Clinical ResultsBiora Therapeutics, a pioneering healthcare company, recently presented clinical data at Digestive Disease Week 202...

Biora Therapeutics, a frontrunner in the biopharmaceutical industry, recently made waves in medical innovation with its announcement on the completion of Multiple-Ascending Dose (MAD) cohorts for the clinical trial of B...

The dawn of a new age in therapeutic management has arrived, as the imminent rise of promising treatments, both in terms of effectiveness and safety, continues to redefine the horizons of our knowledge in medicine. Bior...

Biora Therapeutics Closes $6 Million Offering as Athyrium Capital Management Demonstrates Confidence in Equity HoldingsSAN DIEGO, April 3, 2024 Biora Therapeutics, Inc. (Nasdaq: BIOR), a biotech company focused on revol...

In a recent press release, Biora Therapeutics announced significant developments in its capital structure. The company has successfully finalized definitive agreements for the purchase and sale of 5,454,548 common stock...

Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy AssetIn a significant development, Biora Therapeutics Inc, a leading pharmaceutical company, has successfully generated $3 million in nondilutive capital...

In the pharmaceutical industry, the successful completion of clinical trials is a crucial milestone that marks the progress of a potential therapeutic candidate. This article aims to interpret two key announcements made...

Biora Therapeutics: A Look Ahead at 2024 Catalysts and Revenue ChallengesBiora Therapeutics, a prominent biopharmaceutical company, recently provided insights into its outlook for the year 2024. Exciting developments ar...

Biora Therapeutics, a company known for its innovative solutions in the field of medicine, is marking a new chapter in its research collaboration, demonstrating significant progress for its BioJet Systematic Oral Delive...

Biora Therapeutics Inc., a renowned name in the biopharmaceutical industry, has recently signaled a fresh direction for its endeavors despite consistent revenue decline. The company has announced a strategic collaborati...

Biora Therapeutics Achieves FDA Clearance for Ulcerative Colitis Treatment Utilizing Revolutionary Drug/Device CombinationIn a groundbreaking development, Biora Therapeutics has announced the successful clearance of its...

In a notable move to enhance its equity exposure, Athyrium Capital Management, a prominent investment firm, has executed a convertible notes exchange at a price representing a significant 44% premium to the closing pric...